Distinguished in Primitive Neuroectodermal Tumor (PNET)

Dr. Arati Desai

Oncology
3400 Civic Center Boulevard, West Pavilion, 2nd Floor, 
Philadelphia, PA 
On Staff At
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Distinguished in Primitive Neuroectodermal Tumor (PNET)
3400 Civic Center Boulevard, West Pavilion, 2nd Floor, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Arati Desai is an Oncologist in Philadelphia, Pennsylvania. Dr. Desai is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Gliomatosis Cerebri. Dr. Desai is currently accepting new patients.

Her clinical research consists of co-authoring 64 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Kentucky College Of Medicine
Residency
University of Texas Southwestern Medical Center
Specialties
Oncology
Licenses
Hospice and Palliative Medicine in PA
Board Certifications
Hospice And Palliative Medicine, 2012
Medical Oncology, 2008
Internal Medicine, 2004
Fellowships
UCSF Medical Center and Hospital
Johns Hopkins Hospital
Hospital Affiliations
Hospital Of Univ Of Pennsylvania
Chester County Hospital
Penn Presbyterian Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health Plan
  • INSURANCE PLAN
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
Provider Partners Health Plan
  • MEDICARE SNP
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 20 Less Insurance Carriers -

Locations

Abramson Cancer Center Perelman 2nd Floor West
3400 Civic Center Boulevard, West Pavilion, 2nd Floor, Philadelphia, PA 19104

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Phase 2, Single Arm, Multi-center, Open Label Trial Combining Optune With Concurrent Bevacizumab in the Setting of Recurrent or Progressive Meningioma
A Phase 2, Single Arm, Multi-center, Open Label Trial Combining Optune With Concurrent Bevacizumab in the Setting of Recurrent or Progressive Meningioma
Enrollment Status: Recruiting
Publish Date: June 27, 2025
Intervention Type: Procedure, Device, Biological
Study Phase: Phase 2
Phase 0/I Study of AMG 232 (KRT 232) Concentrations in Brain Tissue in Patients With Recurrent Glioblastoma and of AMG 232 (KRT 232) in Combination With Radiation in Patients With Newly Diagnosed Glioblastoma and Unmethylated MGMT Promoters
Phase 0/I Study of AMG 232 (KRT 232) Concentrations in Brain Tissue in Patients With Recurrent Glioblastoma and of AMG 232 (KRT 232) in Combination With Radiation in Patients With Newly Diagnosed Glioblastoma and Unmethylated MGMT Promoters
Enrollment Status: Terminated
Publish Date: August 20, 2025
Intervention Type: Procedure, Drug, Radiation
Study Drug: KRT-232
Study Phase: Phase 1
Phase I Study of Neoadjuvant GMCI Plus Immune Checkpoint Inhibitor Combined With Standard of Care for Newly Diagnosed High-Grade Gliomas
Phase I Study of Neoadjuvant GMCI Plus Immune Checkpoint Inhibitor Combined With Standard of Care for Newly Diagnosed High-Grade Gliomas
Enrollment Status: Completed
Publish Date: February 14, 2025
Intervention Type: Radiation, Biological, Other, Drug
Study Drugs: AdV-tk, Valacyclovir, Temozolomide, Nivolumab
Study Phase: Phase 1
Phase I/II Study of BGB-290 With Temozolomide in Recurrent Gliomas With IDH1/2 Mutations
Phase I/II Study of BGB-290 With Temozolomide in Recurrent Gliomas With IDH1/2 Mutations
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Drug, Procedure
Study Drugs: BGB-290 PARP Inhibitor, Temozolomide
Study Phase: Phase 1/Phase 2
Phase I Study of AZD1775 (Adavosertib) With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma and Evaluation of Intratumoral Drug Distribution in Patients With Recurrent Glioblastoma
Phase I Study of AZD1775 (Adavosertib) With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma and Evaluation of Intratumoral Drug Distribution in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: January 09, 2025
Intervention Type: Drug, Radiation
Study Drugs: Adavosertib, Temozolomide
Study Phase: Phase 1
A Phase II Study of Binimetinib in Combination With Encorafenib in Adults With Recurrent BRAF V600-Mutated High-Grade Astrocytoma or Other Primary Brain Tumor
A Phase II Study of Binimetinib in Combination With Encorafenib in Adults With Recurrent BRAF V600-Mutated High-Grade Astrocytoma or Other Primary Brain Tumor
Enrollment Status: Terminated
Publish Date: October 31, 2024
Intervention Type: Biological, Drug
Study Drugs: Encorafenib, Binimetinib
Study Phase: Phase 2
Phase II Trial of Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma
Phase II Trial of Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Radiation
Study Drugs: Pembrolizumab, Bevacizumab
Study Phase: Phase 2
Phase I Study to Determine the Safety and Tolerability of the Oral Microtubule Destabilizer BAL101553 in Combination With Standard Radiation in Patients With MGMT Promoter Unmethylated Newly Diagnosed Glioblastoma
Phase I Study to Determine the Safety and Tolerability of the Oral Microtubule Destabilizer BAL101553 in Combination With Standard Radiation in Patients With MGMT Promoter Unmethylated Newly Diagnosed Glioblastoma
Enrollment Status: Terminated
Publish Date: June 24, 2024
Intervention Type: Drug, Radiation
Study Drug: BAL101553
Study Phase: Phase 1
Pilot Surgical PK Study of BGB324 in Recurrent Glioblastoma Patients
Pilot Surgical PK Study of BGB324 in Recurrent Glioblastoma Patients
Enrollment Status: Terminated
Publish Date: February 08, 2024
Intervention Type: Drug
Study Drug: BGB 324
Study Phase: Early Phase 1
A Phase I Trial of Anti-LAG-3 or Anti-CD137 Alone and in Combination With Anti-PD-1 in Patients With Recurrent GBM
A Phase I Trial of Anti-LAG-3 or Anti-CD137 Alone and in Combination With Anti-PD-1 in Patients With Recurrent GBM
Enrollment Status: Completed
Publish Date: October 06, 2023
Intervention Type: Biological, Other
Study Drugs: Anti-LAG-3 Monoclonal Antibody BMS 986016, Anti-PD-1, Anti-CD137
Study Phase: Phase 1
Determining the Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas
Determining the Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas
Enrollment Status: Terminated
Publish Date: October 06, 2023
Intervention Type: Drug
Study Drug: Regadenoson
Study Phase: Phase 1
Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients With Recurrent High Grade Glioma
Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients With Recurrent High Grade Glioma
Enrollment Status: Completed
Publish Date: October 06, 2023
Intervention Type: Other, Drug
Study Drug: Terameprocol
Study Phase: Phase 1
A Phase I and Pilot Study of the Effect of rhIL-7-hyFc (NT-I7) on CD4 Counts in Patients With High Grade Gliomas and Severe Treatment-related CD4 Lymphopenia After Concurrent Radiation and Temozolomide
A Phase I and Pilot Study of the Effect of rhIL-7-hyFc (NT-I7) on CD4 Counts in Patients With High Grade Gliomas and Severe Treatment-related CD4 Lymphopenia After Concurrent Radiation and Temozolomide
Enrollment Status: Terminated
Publish Date: October 06, 2023
Intervention Type: Biological, Other
Study Drug: NT-I7
Study Phase: Phase 1
Single-Arm, Open-Label Phase II Efficacy Study of First-in-Class HIF-2 Alpha Inhibitor, PT2385, for Patients With Recurrent Glioblastoma
Single-Arm, Open-Label Phase II Efficacy Study of First-in-Class HIF-2 Alpha Inhibitor, PT2385, for Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Drug, Other
Study Phase: Phase 2
View 13 Less Clinical Trials

64 Total Publications

Incidence, management, and outcomes of procarbazine-associated hypersensitivity reactions in patients receiving PCV for lower-grade gliomas.
Incidence, management, and outcomes of procarbazine-associated hypersensitivity reactions in patients receiving PCV for lower-grade gliomas.
Journal: Neuro-oncology practice
Published: October 13, 2025
Similar Doctors
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Stephen Bagley
Oncology
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Stephen Bagley
Oncology

Abramson Cancer Center Perelman 2nd Floor West

3400 Civic Center Boulevard, West Pavilion, 2nd Floor, 
Philadelphia, PA 
 (0.1 miles away)
215-615-5858
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Stephen Bagley is an Oncologist in Philadelphia, Pennsylvania. Dr. Bagley is rated as an Elite provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Gliomatosis Cerebri. Dr. Bagley is currently accepting new patients.

Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Michael Salacz
Oncology | Palliative Medicine
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Michael Salacz
Oncology | Palliative Medicine

Capital Health Medical Group

2 Capital Way, Suite 456, 
Pennington, NJ 
 (31.5 miles away)
609-537-7300
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michael Salacz is an Oncologist and a Palliative Medicine provider in Pennington, New Jersey. Dr. Salacz is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

Sanjiv S. Agarwala
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Sanjiv S. Agarwala
Oncology
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Sanjiv S. Agarwala
Oncology
801 Ostrum Street, 
Bethlehem, PA 
 (47.0 miles away)
484-526-2140
Languages Spoken:
English
See accepted insurances

Sanjiv Agarwala is an Oncologist in Bethlehem, Pennsylvania. Dr. Agarwala is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Melanoma, Primitive Neuroectodermal Tumor (PNET), Melanoma of the Eye, and Renal Cell Carcinoma (RCC).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Desai's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 10 Advanced Conditions
View All 36 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile